Reduced Olfactory Bulb Volume Accompanies Olfactory Dysfunction After Mild SARS-CoV-2 Infection: The Hamburg City Health Study COVID Program

Marvin Petersen, MD[a#]; Benjamin Becker, MD[b#]; Maximilian Schell[a], Carola Mayer[a], Felix L. Nägele[a], Elina Petersen, MSc[c,d]; Raphael Twerenbold, MD[c,d,e,f]; Götz Thomalla, MD[a]; Bastian Cheng, MD[a]; Christian Betz, MD[b], Anna S. Hoffmann, MD[b]

[a] Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

[b] Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

[c] Population Health Research Department, University Heart and Vascular Center, Hamburg, Germany

[d] Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany

[e] German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Hamburg, Germany

[f] University Center of Cardiovascular Science, University Heart and Vascular Center, Hamburg, Germany

# These authors contributed equally

Total word count of main manuscript: 3000

Materials & Correspondence

Correspondence and requests for materials should be addressed to

Dr. med. Marvin Petersen

Department of Neurology

University Medical Center Hamburg-Eppendorf

Martinistraße 52, 20246 Hamburg, Germany

+4940-7410-59094

Key Points

Question: Is olfactory dysfunction associated with alterations of the olfactory bulb in individuals who recovered from mild to moderate SARS-CoV-2 infection?

Findings: 17.5% of investigated individuals exhibited long term olfactory dysfunction. Olfactory bulb volume was lower in individuals with post-acute olfactory dysfunction and predicted long-term olfactory function.

Meaning: Our results demonstrate the link between olfactory function and olfactory bulb integrity after SARS-CoV-2 infection, rendering olfactory bulb volume a promising surrogate marker of long-term smelling outcomes in COVID-19.

Abstract

Importance: Olfactory dysfunction is a frequent sequel of SARS-CoV-2 infection. Despite its prevalence, the SARS-CoV-2-related pathophysiology of olfactory dysfunction remains not well understood.

Objective: Determine whether long-term olfactory dysfunction in mild to moderate SARS-CoV-2 infection corresponds with structural alteration of the olfactory bulb.

Design, Setting and Participants: Data of non-vaccinated COVID-19 convalescents recruited between 1st March and 31st December 2020 were analyzed. Within the framework of the Hamburg City Health Study COVID Program, participants underwent magnetic resonance imaging (MRI) and neuropsychological testing as well as a structured questionnaire for olfactory function. In addition, olfactory function was assessed at an additional timepoint between 15th March and 15th April 2022 including quantitative olfactometric testing with Sniffin' Sticks.

Exposure: SARS-CoV-2 infection confirmed by a positive polymerase chain reaction test (PCR).

Main Outcomes and Measures: Primary study outcomes were olfactory dysfunction and the MRI-based measurement of olfactory bulb volume.

Results: This study included 233 individuals recovered from mainly mild to moderate SARS-CoV-2 infections (44.2% female, age [years], mean ± SD, 55.79 ± 7.25). Longitudinal assessment demonstrated a declining prevalence of olfactory

dysfunction from 67.1% at acute infection, 21.0% at baseline examination (mean ± SD, 8.31 ± 2.77 months post infection) and 17.5% at follow-up (mean ± SD, 21.8 ± 3.61 months post infection). Participants with post-acute olfactory dysfunction had a significantly lower olfactory bulb volume [mm^3] at scan-time than normally smelling individuals (mean ± SD, baseline: 40.76 ± 13.08 vs. 46.74 ± 13.66, f = 4.07, p = 0.046; follow-up: 40.45 ± 12.59 vs. 46.55 ± 13.76, f = 4.50, p = 0.036). Olfactory bulb volume predicted olfactometric scores at follow-up (r_{sp} = 0.154, p = 0.025). Performance in neuropsychological testing was not significantly associated with the olfactory bulb volume.

Conclusions: Our work demonstrates the association of olfactory dysfunction and olfactory bulb integrity in a sample of individuals recovered from mainly mild to moderate COVID-19. Olfactory bulb volume was demonstrably lower in individuals with sustained olfactory dysfunction and predicted long-term smelling function longitudinally. Collectively, our results highlight olfactory bulb volume as a surrogate marker that may inform diagnosis and guide rehabilitation strategies in COVID-19.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected societies worldwide. Olfactory dysfunction is among the most common symptoms in COVID-19 with a reported prevalence of up to 85%.[1–8] COVID-19 features olfactory dysfunction in varying degrees – e.g., anosmia, hyposmia or parosmia – which occur often before the onset of respiratory symptoms.[3] Compared to other COVID-19-related symptoms like cough, fever or fatigue, olfactory dysfunction proved to be more predictive of SARS-CoV-2 infection.[9,10] Despite its relevance, the understanding of the pathophysiology of SARS-CoV-2-related olfactory dysfunction is still incomplete.

There is ongoing research in the mechanisms of COVID-19-related olfactory dysfunction. Commonly, anosmia in the absence of rhinorrhea or nasal congestion is described as an early symptom which suggests other causal mechanisms than a common cold with conductive deficits causing olfactory dysfunction.[3,4,11,12] SARS-CoV-2 might affect the olfactory system at different breakpoints of its trajectory ranging from disruption of sustentacular cells and olfactory sensory neurons situated in the olfactory mucosa to functional disarray of the olfactory cortex.[13,14] Yet, there is only vague understanding of how these aspects relate to clinical outcomes.

Magnetic resonance imaging (MRI) provides a promising avenue to investigate the pathomechanistic substrates of olfactory dysfunction in SARS-CoV-2 infection in vivo. Previous MRI studies put emphasis on the integrity of the olfactory bulb (OB) as a structural correlate of olfactory function in general.[15–17] Volume reduction of the OB accompanies olfactory loss in conditions like acute or chronic rhinosinusitis and head

trauma.[18] Abnormalities in psychophysical olfactory testing are demonstrably associated with OB volume alterations in health and disease.[19–21] Furthermore, the duration and degree of olfactory loss is proportional to the OB volume.[22] So far, studies relating OB volumetry and olfactory function in COVID-19 rely on case reports and small sample sizes yielding heterogeneous results.[14,23–27] Therefore, further investigations are warranted.

Based on previous evidence, we hypothesized that olfactory dysfunction in COVID-19 corresponds with interindividual volumetric differences of the OB. To address this hypothesis, we quantified the OB volume based on structural MRI and performed a longitudinal assessment of olfactory function in a large sample of individuals recovered from mainly mild to moderate COVID-19. As affection of the olfactory system might precede COVID-19-related neuropathology, we additionally probed for a relationship of OB alterations and neuropsychological test score results in an exploratory analysis. With this work we aimed to further the understanding of the effects SARS-CoV-2 exerts on the olfactory system and thus deepen our insight in the pathophysiology underlying the clinical sequelae of COVID-19.

Methods

Study population and clinical examination

In this work we investigated data from participants of the Hamburg City Health Study (HCHS) Covid Program with available MRI data. A detailed description of the study design has been published separately.[28,29] Our reporting complies with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement guidelines.[30] In brief, citizens of the city of Hamburg, Germany, were considered for enrollment if they met two criteria: (1) a laboratory-confirmed positive

polymerase chain reaction (PCR) test for SARS-CoV-2, which was obtained between 1st March and 31st December 2020 but at least 4 months prior to study enrollment; (2) age between 45 and 74 years at the time of inclusion. An invitation was issued upon identification via the clinical information system of the University Medical Center Hamburg-Eppendorf or a response to a public call for participation. Recruited participants underwent an extended study protocol of the Hamburg City Health Study (HCHS): besides the standard HCHS work up including MRI and assessment of cognitive function (Trail Making Test B, Word List Recall, Animal Naming Test, Mini Mental State Exam), depressive symptoms (PHQ-9) and quality of life (EQ-5D), participants were required to retrospectively report on disease severity and SARS-CoV-2-associated symptoms via a structured questionnaire.[31] The presented study was only conducted based on the post-SARS-CoV-2 cohort – i.e., the matched cohort of control subjects as described previously could not be leveraged as the required high-resolution T2-weighted MRI data was not available.[28,29] To assess the trajectory of olfactory function, participants were reinvited between 15th March and 15th April 2022. Follow-up investigations comprised a structured questionnaire regarding olfactory function as well as olfactometric assessment via Sniffin' Sticks Screening 12 test by two trained otorhinolaryngologists (B.B., A.S.H.).[32,33] The test score ranges from 0 to 12 (0-6: anosmia, 7-10: hyposmia, 11-12: normosmia) and is based on normative information derived from more than 1200 patients assessed with Sniffin' Sticks Screening and olfactive evoked potentials. Eventually, information about olfactory dysfunction from structured questionnaires was available for three timepoints: (1) during the acute infection, (2) at the baseline investigation and (3) at follow-up. MRI and neuropsychological testing were only performed during baseline examination.

Ethics approval

Written informed consent was obtained from all participants. The study was approved by the local ethics committee of the Landesärztekammer Hamburg (State of Hamburg Chamber of Medical Practitioners, PV5131) and conducted complying with the Declaration of Helsinki.[34]

MRI acquisition

High-resolution 3D T2-weighted images were acquired at baseline on a 3T scanner (MAGNETOM™Skyra, Siemens Healthineers, Erlangen, Germany) with the following sequence parameters: TR=3200 ms, TE=407 ms, 256 axial slices, ST=0.94 mm, and IPR=0.9×0.9mm.

Olfactory bulb segmentation

We performed OB segmentation on high-resolution T2-weighted images leveraging a novel fully-automated deep learning-based pipeline specifically designed for OB volumetry.[35] All resulting segmentations underwent visual quality assessment. Exemplary segmentation results are illustrated in *figure 1* as well as *supplementary materials S1*. The summed volume of both OBs was used for further analysis.

Statistical analysis

OB volume and olfactometry scores were compared between individuals with and without questionnaire-assessed olfactory dysfunction at different timepoints employing analyses of covariance (ANCOVA). Multiple linear regression analysis was performed for assessing the linear relationship of olfactometry scores, as well as neuropsychiatric scores with OB volume. A further ANCOVA was performed to test whether the OB volume at baseline differed between individuals with sustained olfactory dysfunction at follow-up and those that recovered until then. The association between the time interval from positive PCR to examination was assessed via

Spearman correlation. Age, sex and smoking behavior were included as covariates in ANCOVAs and linear models as they represent potential confounders.[36] Statistical computations and plotting were performed in Python 3.9.7 harnessing matplotlib (v.3.5.1), numpy (v.1.22.3), pandas (v.1.4.2), pingouin (v.0.5.1) and seaborn (v.0.11.2).[37–41]

Results

Sample characteristics

Data from 233 HCHS Covid Program participants was available for primary analysis. Nine subjects were excluded pre-analysis: 3 since they reported to have had olfactory dysfunction before their SARS-CoV-2 infection, 3 because of a missing OB and 3 because of erroneous segmentations. Thus, data from n=224 participants were available for the final analysis. Sample characteristics are summarized in *table 1*. On average participants were 55.79 ±7.25 (mean ±SD) years old, 44.2% were female and 5.4% were current smokers. 8.4% of participants were hospitalized due to COVID-19.

Longitudinal trajectory of olfactory function

The baseline examination happened on average 253 days after the positive PCR test prompting recruitment, the follow-up at 663 days. 143 participants were available at follow-up. Of these, 67.1% (n=96) described olfactory dysfunction during the acute phase of infection, 21.0% (n=30) at the baseline examination and 17.5% (n=25) at follow-up (*figure 2a*). Assessment of olfactory dysfunction severity via the visual analogue scale resulted in a coherent trajectory: 7.62 ±2.76 (acute infection), 3.79 ±1.78 (baseline), 2.96 ±2.10 (follow-up).

Olfactometry

To assess long term olfactory outcomes, olfactometry with the Sniffin' Sticks Screening 12 test was performed on participants at follow-up. Olfactometry scores at follow-up were 10.18 ±1.78 (mean ±SD). Participants with self-reported olfactory dysfunction at the acute infection did not differ from normally smelling participants regarding olfactometry scores at follow-up (mean ±SD, 10.04 ±1.97 vs. 10.46 ±1.31, eta_p^2=0.01, *p*=0.211; *figure 2b*). Yet, participants with olfactory dysfunction at baseline had lower olfactometric scores than normally smelling individuals (mean ± SD, 8.67 ± 2.62 vs. 10.58 ±1.22, eta_p^2=0.19, *p*<0.005) and the same applied for participants impaired at follow-up (mean ±SD, 8.40 ±2.74 vs. 10.56 ±1.22, eta_p^2=0.22, *p*<0.005).

Olfactory bulb volume and olfactory function

The mean OB volume was 45.53 ±12.85 mm³. The ANCOVA yielded no significant group difference in OB volume at acute infection between individuals with and without olfactory dysfunction (mean ±SD, 45.85 ±12.92 vs. 45.21 ±15.16, eta_p^2=0.00, *p*=0.837; *figure 2c*). Individuals with self-reported sustained olfactory dysfunction at baseline and at follow-up had significantly lower OB volume than normally smelling subjects at that time (mean ±SD, baseline: 40.76 ±13.08 vs. 46.74 ±13.66, eta_p^2=0.03, *p*=0.046; follow-up: 40.45 ±12.59 vs. 46.55 ±13.76, eta_p^2=0.03, *p*=0.036). In participants with olfactory dysfunction lower OB volume was accompanied by a shorter time-period between a positive PCR for SARS-CoV-2, signifying the timepoint of acute SARS-CoV-2 infection, and the baseline examination (r_{sp}=0.161, *p*=0.016; *figure 2d*).

Longitudinal prediction of olfactory function

OB volume derived from MRI at baseline was significantly linearly associated with olfactometry scoring at follow-up (r_{sp}=0.154, *p*=0.025; *figure 2e*). Participants with

sustained olfactory dysfunction at follow-up had lower OB volume at baseline (mean ±SD, 40.64 ±12.83 vs. 47.58 ±12.58, eta_p^2=0.06, *p*=0.018; *figure 2f*) than those that had recovered by the time of reassessment.

Clinical analysis

To further explore potential clinical implications of our findings, correlations of OB volume and neuropsychological cognitive test scores and psychiatric test scores were performed. To summarize, no significant associations of OB volume and scores of the Trail Making Test B (r_{sp}=0.014, *p*=0.722), Animal Naming Test (r_{sp}=-0.090, *p*=0.069), Word List Recall Test (r_{sp}=-0.050, *p*=0.587), Mini Mental State Exam (r_{sp}=-0.025, *p*=0.689), PHQ-9 (r_{sp}=0.098, *p*=0.404) and EQ-5D (r_{sp}=-0.009, *p*=0.306) were found. Corresponding visualizations are displayed in *supplementary materials S2*.

Discussion

We report on an association of OB volume and olfactory dysfunction in a large sample of mainly mildly to moderately affected COVID-19 convalescents. Longitudinal assessment demonstrated sustained olfactory dysfunction up to two years after acute infection. Participants suffering from olfactory dysfunction beyond acute infection had a significantly lower OB volume at baseline than normally smelling individuals. Moreover, OB volume was predictive for olfactometric performance in the Sniffin' Sticks test 22 months after the acute infection as well as for the binary outcome of recovery from olfactory dysfunction at follow-up. Neuropsychological test performances were not significantly associated with OB volume. Taken together, our findings suggest that lower volume of the OB may be a promising surrogate marker of smelling function in COVID-19 at post-acute disease stages.

Its frequency and the concomitant effects on quality of life render olfactory dysfunction a burdensome symptom of COVID-19. Our 2-year longitudinal assessment of olfactory function provided insights about time-dependent development of these symptoms. At acute infection, the proportion of participants reporting olfactory dysfunction was 67.1% which is coherent with previous study reports ranging from 30% to 85%.[1–4,6,7] After the acute infection, the prevalence decreased to 21% at the baseline examination (on average 253 days post infection) and 17.5% at follow-up (on average 664 days post infection; *figure 2a*). These numbers support previous literature finding high rates of long term olfactory dysfunction in COVID-19.[42–44] Of note, a recent meta-analysis reports persistent olfactory dysfunction in less patients (11.6%; 95% confidence interval 5.2% to 23.9%).[45] We attribute this difference to design differences with respect to our work: the studies included in the meta-analysis also considered young adults (>18 years) possibly exhibiting higher regenerative capacity as well as recent SARS-CoV-2 variants demonstrably affecting patient olfaction less severely than the wild type variant mainly prevalent at the pandemic onset.[46] Overall, these findings indicate that although most former COVID-19 patients completely recover, subjective olfactory dysfunction persisted in relevant proportion of individuals.

To assess long term olfactory outcomes, olfactometry with the Sniffin' Sticks Screening 12 test was performed at follow-up. Participants suffering from olfactory dysfunction beyond the acute infection, plausibly showed significantly lower olfactometry scores than normally smelling or recovering subjects (*figure 2b*). Collectively, our results support previous evidence of sustained olfactory dysfunction

in around 20% of patients underscoring the possible long lasting burden following a SARS-CoV-2 infection.[6,43]

Olfactory dysfunction is demonstrably accompanied by lower OB volume in many otorhinolaryngological conditions like post-infectious olfactory disorder, head trauma as well as acute and chronic rhinosinusitis.[18] In line with this notion, our work showed a lower OB volume in individuals with sustained olfactory dysfunction after the acute SARS-CoV-2 infection indicating COVID-19-related OB atrophy (*figure 2c*). Thus, our results corroborate previous reports derived from case studies and small samples suggesting lower OB volume in SARS-CoV-2-induced olfactory dysfunction.[23–26]

Previous reports demonstrated an inverse correlation between OB volume and the duration of symptoms in post-infectious olfactory disorder suggesting its predictive capacity.[22] To further investigate this, we related the OB volume with olfactometry scores which were acquired approximately 1 year after the MRI. Notably, the OB volume predicted olfactometry scores at follow-up (*figure 2e*). Yet, the observed correspondence was of a rather low degree, indicating that further determinants of long-term olfactory dysfunction should be considered. Possibly, MRI assessment closer to the acute infection would have resulted in the observation of stronger effects. Furthermore, OB volume was higher in participants in which the smelling sense fully recovered until follow-up compared to those with sustained olfactory dysfunction (*figure 2f*). Hence, the OB volume appears to be a predictor of recovery from olfactory dysfunction, i.e., potentially capturing the severity of damage SARS-CoV-2 exerts on the olfactory system. Interestingly, individuals exhibited higher OB volume the longer the time interval between the positive PCR and the MRI was (*figure 2d*). This might indicate that an increasing OB volume may reflect recovery of

olfactory function. However, longitudinal imaging assessment is warranted here. Taken together, these findings suggest that a lower OB volume indicates more severe disruption of the olfactory system and predict persistent olfactory dysfunction in COVID-19 patients. Therefore, the OB might serve as a promising diagnostical target for prognosis assessment and even therapeutical monitoring of olfactory dysfunction in COVID-19.

There are multiple potential mechanisms that might explain the observed link between olfactory dysfunction and OB dysintegrity. In the olfactory mucosa, olfactory sensory neurons (OSN) – sensing molecular signatures as odor information – as well as supporting epithelial cells (sustentacular cells) ensure proper sense of smell. Sustentacular cells express angiotensin-converting enzyme 2 (ACE-2) and appear to be a major infection target of the virus.[13,47] As they support OSN in a glial-like fashion, impairment of sustentacular cells is considered to contribute to COVID-19-related olfactory dysfunction.[48] How OSN are affected by SARS-CoV-2 is controversial. Discussed mechanisms are neurotropism, affection by an impaired support system and damage caused by the immune response to the virus.[13,48,49] Recent analyses failed to detect signs of neurotropism and neural invasion through SARS-CoV-2 challenging the notion of the olfactory system serving the virus as an entry point.[48,50,51] As the OB serves as a relay for projections from the OSN, volumetric reductions might occur as an effect of indirect OSN affection - e.g., via inflammation or microvasculopathy – rather than direct damage from the virus leading to reduced tissue integrity.[51] Taking the link between OB integrity and long-term olfactory function into account, OB volume might serve as an indicator of severe structural disruption of the olfactory system which corresponds with unfavorable

outcomes. Nonetheless, further longitudinal neuroimaging research is warranted to support this notion.

By now, COVID-19 is recognized to cause post-acute neurological and psychiatric symptoms like executive dysfunction, fatigue, anxiety, depression and sleep impairment.[52–56] Coherent with these observations, a comprehensive MRI analysis on COVID-19 convalescents from the UK Biobank has shown widespread gray matter volume reductions in areas receiving projections from the olfactory cortex.[53] Its evident exposition to deleterious SARS-CoV-2 effects renders the OB a candidate indicator of COVID-19-related neuropathology beyond the olfactory system. Thus, we tested whether the OB volume is associated with results of neuropsychological test scores. OB volume showed no significant association with tests of cognitive function (Trail Making Test B, Word List Recall, Animal Naming Test), depressive symptoms (Patient Health Questionnaire-9, PHQ-9) and quality of life (EQ-5D). Consequently, pathology of the olfactory system might be disjunct to non-olfaction-related neuropathology in SARS-CoV-2 infection. Nonetheless, our findings might be partially attributable to the overall mild to moderate disease course captured in our sample resulting in negative results. Further investigations of determinants of neurological and psychiatric sequelae of COVID-19 are necessary.

The strengths of this work lie in its considerable sample size; high quality imaging and phenotypical data; a modern fully-automated MRI-based segmentation of the OB enabling volumetry at scale; olfactory assessment at different time points post infection, including quantitative olfactory testing (at follow-up) providing longitudinal information for up to 2 years. Yet, this study has some limitations. First, MRI acquisition and olfactometry with Sniffin' sticks were performed only at one timepoint,

which makes it difficult to completely address pre-infectious group differences. For instance, our results could partially be explained by individuals with lower OB volume being more susceptible to olfactory dysfunction caused by SARS-CoV-2 infection. Previous work hypothesizes that smaller OB volume and pre-existing reduced number of olfactory receptor neurons increased the patient's vulnerability to develop post-infectious olfactory loss. With less functional tissue existing in the first place, damage to existing sensory cells might lead to more pronounced olfactory dysfunction.[57] Here, evidence from future longitudinal studies is warranted. As more severely impaired individuals might be more motivated and thus more likely to participate in our study than the average population, our results could possibly be influenced by our recruitment strategy. Lastly, the different SARS-CoV-2 strains appear to differ in terms of olfactory dysfunction frequency and intensity. Our study lacks information about SARS-CoV-2 strains rendering it incapable to address inter-strain differences. However, the investigation started at an early stage of the pandemic most likely soothing the problem of different COVID-19 strains and vaccinations as confounders.

Conclusion

In this work, we performed an assessment of OB volumetry as a neuroimaging marker of olfactory dysfunction in patients recovered from mainly mild to moderate COVID-19. By revealing an alteration of the OB in participants with olfactory dysfunction, our results highlight the relevance of the olfactory system in the overall pathophysiology of the disease. However, a connection between OB volume and neuropsychological signs of COVID-19 could not be established. Collectively, these results demonstrate that the OB is a promising target for assessment of olfactory

dysfunction in COVID-19 potentially facilitating diagnosis and informing therapy-related decisions.

Acknowledgments

We describe contributions to the paper using the CRediT contributor role taxonomy. Conceptualization: M.P, A.S.H.; Data Curation: M.P., B.B., M.S., C.M., F.N., A.S.H.; Formal analysis: M.P.; Funding acquisition: G.T, B.C, C.B., A.S.H.; Investigation: M.P., B.B., M.S., C.M., F.N., E.P., R.T., G.T., B.C., C.B., A.S.H.; Methodology: M.P.; Software: M.P.; Supervision: C.B, A.S.H.; Visualization: M.P.; Writing—original draft: M.P., B.B.; Writing—review & editing: M.P., B.B., M.S., C.M., F.N., E.P., R.T., G.T., B.C., C.B., A.S.H.

Data access: M.P., B.B., and A.S.H. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

The authors wish to acknowledge all participants of the Hamburg City Health Study and cooperation partners, patrons and the Deanery from the University Medical Center Hamburg—Eppendorf for supporting the Hamburg City Health Study. Special thanks applies to the staff at the Epidemiological Study Center for conducting the study. The participating institutes and departments from the University Medical Center Hamburg-Eppendorf contribute all with individual and scaled budgets to the overall funding. The Hamburg City Health Study is also supported by Amgen, Astra Zeneca, Bayer, BASF, Deutsche Gesetzliche Unfallversicherung (DGUV), DIFE, the Innovative medicine initiative (IMI) under grant number No. 116074 and the Fondation Leducq under grant number 16 CVD 03., Novartis, Pfizer, Schiller, Siemens, Unilever and “Förderverein zur Förderung der HCHS e.V.”. The publication has been approved by the Steering Board of the Hamburg City Health Study.

GT has received fees as consultant or lecturer from Acandis, Alexion, Amarin, Bayer, Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daichi Sankyo, Portola, and

Stryker outside the submitted work. The remaining authors declare no conflicts of interest.

This work was supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), Schwerpunktprogramm (SPP) 204 – project number 454012190 – and Sonderforschungsbereich (SFB) 936 – project number 178316478 – Project C2 (M.P., C.M., G.T., and B.C.).

Data will be made available on reasonable request from any qualified investigator after evaluation of the request by the Steering Board of the HCHS. Analysis code and documentation is publicly available on GitHub (https://github.com/csi-hamburg/CSIframe/blob/main/pipelines/obseg/obseg.sh, https://github.com/csi-hamburg/CSIframe/wiki/Olfactory-bulb-segmentation and https://github.com/csi-hamburg/2022_petersen_ob_postcovid).

References

1. von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. *ACS Chem Neurosci.* 2020;11(19):2944-2961. doi:10.1021/acschemneuro.0c00460

2. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. *Neuroscientist*. 2021;27(6):582-603. doi:10.1177/1073858420956905

3. Cooper KW, Brann DH, Farruggia MC, et al. COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. *Neuron*. 2020;107(2):219-233. doi:10.1016/j.neuron.2020.06.032

4. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol.* 2020;277(8):2251-2261. doi:10.1007/s00405-020-05965-1

5. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and Complete Olfactory Loss of Function as a Possible Symptom of COVID-19. *JAMA Otolaryngology–Head & Neck Surgery*. 2020;146(7):674-675. doi:10.1001/jamaoto.2020.0832

6. Lechien JR, Chiesa-Estomba CM, Beckers E, et al. Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. *J Intern Med*. 2021;290(2):451-461. doi:10.1111/joim.13209

7. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. *Mayo Clinic Proceedings*. 2020;95(8):1621-1631. doi:10.1016/j.mayocp.2020.05.030

8. Parma V, Ohla K, Veldhuizen MG, et al. More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis. *Chem Senses*. 2020;45(7):609-622. doi:10.1093/chemse/bjaa041

9. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. 2020;10(8):944-950. doi:10.1002/alr.22587

10. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med*. 2020;26(7):1037-1040. doi:10.1038/s41591-020-0916-2

11. Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. *Head Neck*. 2020;42(6):1252-1258. doi:10.1002/hed.26204

12. Ahmed AK, Sayad R, Mahmoud IA, et al. “Anosmia” the mysterious collateral damage of COVID-19. *J Neurovirol*. Published online March 5, 2022. doi:10.1007/s13365-022-01060-9

13. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci*. 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5

14. Esposito F, Mario Cirillo, Rosa De Micco, et al. Olfactory loss and brain connectivity after COVID -19. *Human Brain Mapping*. Published online January 27, 2022. doi:10.1002/hbm.25741

15. Haehner A, Rodewald A, Gerber JC, Hummel T. Correlation of Olfactory Function With Changes in the Volume of the Human Olfactory Bulb. *Archives of Otolaryngology–Head & Neck Surgery*. 2008;134(6):621-624. doi:10.1001/archotol.134.6.621

16. Lu R, Aziz NA, Reuter M, Stöcker T, Breteler MMB. Evaluation of the Neuroanatomical Basis of Olfactory Dysfunction in the General Population. *JAMA Otolaryngology–Head & Neck Surgery*. 2021;147(10):855-863. doi:10.1001/jamaoto.2021.2026

17. Das S. Olfactory Bulb Volume—A Novel Preclinical Biomarker for Smell Loss and Neurodegenerative Disease. *JAMA Otolaryngology–Head & Neck Surgery*. 2021;147(10):864-865. doi:10.1001/jamaoto.2021.2038

18. Hummel T, Urbig A, Huart C, Duprez T, Rombaux P. Volume of olfactory bulb and depth of olfactory sulcus in 378 consecutive patients with olfactory loss. *J Neurol*. 2015;262(4):1046-1051. doi:10.1007/s00415-015-7691-x

19. Rombaux P, Mouraux A, Bertrand B, Nicolas G, Duprez T, Hummel T. Retronasal and orthonasal olfactory function in relation to olfactory bulb volume in patients with posttraumatic loss of smell. *Laryngoscope*. 2006;116(6):901-905. doi:10.1097/01.mlg.0000217533.60311.e7

20. Rombaux P, Weitz H, Mouraux A, et al. Olfactory function assessed with orthonasal and retronasal testing, olfactory bulb volume, and chemosensory event-related potentials. *Arch Otolaryngol Head Neck Surg*. 2006;132(12):1346-1351. doi:10.1001/archotol.132.12.1346

21. Rombaux P, Martinage S, Huart C, Collet S. Post-infectious olfactory loss: a cohort study and update. *B-ENT*. 2009;5 Suppl 13:89-95.

22. Yao L, Yi X, Pinto JM, et al. Olfactory cortex and Olfactory bulb volume alterations in patients with post-infectious Olfactory loss. *Brain Imaging Behav*. 2018;12(5):1355-1362. doi:10.1007/s11682-017-9807-7

23. Chiu A, Fischbein N, Wintermark M, Zaharchuk G, Yun PT, Zeineh M. COVID-19-induced anosmia associated with olfactory bulb atrophy. *Neuroradiology*. 2021;63(1):147-148. doi:10.1007/s00234-020-02554-1

24. Altunisik E, Baykan AH, Sahin S, Aydin E, Erturk SM. Quantitative Analysis of the Olfactory System in COVID-19: An MR Imaging Study. *AJNR Am J Neuroradiol*. 2021;42(12):2207-2214. doi:10.3174/ajnr.A7278

25. Güney B, Bacaksızlar Sarı F, Özdemir MY, Çullu N, Doğan E, Togan T. Changes in olfactory bulbus volume and olfactory sulcus depth in the chronic period after COVID-19 infection. *Acta Otolaryngol*. 2021;141(8):786-790. doi:10.1080/00016489.2021.1946138

26. Tsivgoulis G, Fragkou PC, Lachanis S, et al. Olfactory bulb and mucosa abnormalities in persistent COVID-19-induced anosmia: a magnetic resonance imaging study. *Eur J Neurol*. 2021;28(1):e6-e8. doi:10.1111/ene.14537

27. Frosolini A, Parrino D, Fabbris C, et al. Magnetic Resonance Imaging Confirmed Olfactory Bulb Reduction in Long COVID-19: Literature Review and Case Series. *Brain Sciences*. 2022;12(4):430. doi:10.3390/brainsci12040430

28. Petersen EL, Goßling A, Adam G, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. *European Heart Journal*. Published online January 6, 2022:ehab914. doi:10.1093/eurheartj/ehab914

29. Petersen M, Nägele FL, Mayer C, et al. Brain imaging and neuropsychological assessment of individuals recovered from mild to moderate SARS-CoV-2 infection. Published online July 9, 2022:2022.07.08.22277420. doi:10.1101/2022.07.08.22277420

30. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X

31. Petersen M, Nägele FL, Mayer C, et al. Brain network architecture constrains age-related cortical thinning. *NeuroImage*. 2022;264:119721. doi:10.1016/j.neuroimage.2022.119721

32. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. *Rhinol Suppl*. 2017;54(26):1-30. doi:10.4193/Rhino16.248

33. Hummel T, Welge-Lüssen A. Assessment of olfactory function. *Adv Otorhinolaryngol*. 2006;63:84-98. doi:10.1159/000093752

34. Petersen M, Frey BM, Schlemm E, et al. Network Localisation of White Matter Damage in Cerebral Small Vessel Disease. *Scientific Reports*. 2020;10(1):9210. doi:10.1038/s41598-020-66013-w

35. Estrada S, Lu R, Diers K, et al. Automated olfactory bulb segmentation on high resolutional T2-weighted MRI. *NeuroImage*. 2021;242:118464. doi:10.1016/j.neuroimage.2021.118464

36. Fitzek M, Patel PK, Solomon PD, et al. Integrated age-related immunohistological changes occur in human olfactory epithelium and olfactory bulb. *J Comp Neurol*. 2022;530(12):2154-2175. doi:10.1002/cne.25325

553 37. Caswell TA, Droettboom M, Lee A, et al. matplotlib/matplotlib: REL: v3.5.2. Published
554 online May 3, 2022. doi:10.5281/zenodo.6513224

555 38. Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy. *Nature*.
556 2020;585(7825):357-362. doi:10.1038/s41586-020-2649-2

557 39. Reback J, McKinney W, jbrockmendel, et al. pandas-dev/pandas: Pandas 1.0.3. Published
558 online March 18, 2020. doi:10.5281/zenodo.3715232

559 40. Vallat R. Pingouin: statistics in Python. *JOSS*. 2018;3(31):1026. doi:10.21105/joss.01026

560 41. Waskom ML. seaborn: statistical data visualization. *Journal of Open Source Software*.
561 2021;6(60):3021. doi:10.21105/joss.03021

562 42. Mendes Paranhos AC, Nazareth Dias ÁR, Machado da Silva LC, et al. Sociodemographic
563 Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory
564 Dysfunction. *JAMA Network Open*. 2022;5(9):e2230637.
565 doi:10.1001/jamanetworkopen.2022.30637

566 43. Boscolo-Rizzo P, Hummel T, Hopkins C, et al. High prevalence of long-term olfactory,
567 gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-
568 control study with one-year follow-up using a comprehensive psychophysical evaluation.
569 *Rhinology*. 2021;59(6):517-527. doi:10.4193/Rhin21.249

570 44. Lucidi D, Molinari G, Silvestri M, et al. Patient-reported olfactory recovery after SARS-
571 CoV-2 infection: A 6-month follow-up study. *Int Forum Allergy Rhinol*. 2021;11(8):1249-
572 1252. doi:10.1002/alr.22775

573 45. Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in
574 patients with covid-19: meta-analysis with parametric cure modelling of recovery curves.
575 *BMJ*. 2022;378:e069503. doi:10.1136/bmj-2021-069503

576 46. Klimek L, Hagemann J, Hummel T, et al. Olfactory dysfunction is more severe in wild-type
577 SARS-CoV-2 infection than in the Delta variant (B.1.617.2). *World Allergy Organization*
578 *Journal*. 2022;15(6):100653. doi:10.1016/j.waojou.2022.100653

579 47. Chen M, Shen W, Rowan NR, et al. Elevated ACE-2 expression in the olfactory
580 neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and
581 replication. *Eur Respir J*. 2020;56(3):2001948. doi:10.1183/13993003.01948-2020

582 48. Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-
583 CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. *Cell*.
584 2021;184(24):5932-5949.e15. doi:10.1016/j.cell.2021.10.027

585 49. Clara B, Audrey SA, Ophélie AG, et al. *Neutrophils Initiate the Destruction of the Olfactory*
586 *Epithelium during SARS-CoV-2 Infection in Hamsters*. Immunology; 2022.
587 doi:10.1101/2022.03.15.484439

588 50. Khan M, Clijsters M, Choi S, et al. Anatomical barriers against SARS-CoV-2 neuroinvasion
589 at vulnerable interfaces visualized in deceased COVID-19 patients. *Neuron*.
590 2022;110(23):3919-3935.e6. doi:10.1016/j.neuron.2022.11.007

591 51. Ho CY, Salimian M, Hegert J, et al. Postmortem Assessment of Olfactory Tissue
592 Degeneration and Microvasculopathy in Patients With COVID-19. *JAMA Neurol*.
593 Published online April 11, 2022. doi:10.1001/jamaneurol.2022.0154

594 52. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19
595 neurology: clinical, radiological and laboratory findings. *Brain*. 2020;143(10):3104-3120.
596 doi:10.1093/brain/awaa240

597 53. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain
598 structure in UK Biobank. *Nature*. Published online March 7, 2022:1-17.
599 doi:10.1038/s41586-022-04569-5

600 54. Carfì A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study
601 Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020;324(6):603-
602 605. doi:10.1001/jama.2020.12603

603 55. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients
604 discharged from hospital: a cohort study. *The Lancet*. 2021;397(10270):220-232.
605 doi:10.1016/S0140-6736(20)32656-8

606 56. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of
607 COVID-19. *Nature*. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9

608 57. Patterson A, Hähner A, Kitzler HH, Hummel T. Are small olfactory bulbs a risk for
609 olfactory loss following an upper respiratory tract infection? *Eur Arch Otorhinolaryngol*.
610 2015;272(11):3593-3594. doi:10.1007/s00405-015-3524-x

611

Figure captions

Figure 1: Exemplary 3D visualization of olfactory bulb segmentation results. Volumetric visualization of the left and right olfactory bulb (highlighted) and surrounding brain areas. a) coronal, anterior-posterior; b) axial, inferior-superior; c) sagittal, right-left.

Figure 2: Association of olfactory bulb volume and olfactory function. a) Trajectory of olfactory function along timepoints. Blue dots indicate proportion of individuals with olfactory dysfunction. Gray dots show the average impairment as operationalized by the visual analogue scale. b) Group differences of olfactometry scores at follow-up between participants with and without olfactory dysfunction at different timepoints. As found with respect to olfactory bulb volume, olfactometry scores at follow-up were significantly lower in individuals that exhibited olfactory dysfunction during both examination timepoints but not during the acute infection. c) Group differences of olfactory bulb volume at baseline between participants with and without olfactory dysfunction with respect to different timepoints. Olfactory bulb volume at baseline was significantly lower in individuals that exhibited olfactory dysfunction during both examination timepoints but not during the acute infection. d) Association of the time interval from positive PCR to examination and olfactory bulb volume. A smaller interval was significantly associated with lower olfactory bulb volume. e) Linear associations between olfactory bulb volume and olfactometry scores. A low olfactory bulb volume at baseline was significantly associated with a lower olfactometry score at follow-up. f) Group differences of olfactory bulb volume between participants with sustained olfactory dysfunction at follow-up and those with recovered olfaction to that point. Olfactory bulb volume was significantly lower in participants with sustained olfactory dysfunction. Abbreviations: eta_p^2 = partial eta squared indicating the effect

size as provided by the analysis of covariance, p = p-value, r_{sp} = spearman correlation coefficient, PCR = polymerase chain reaction, T1 = at baseline, T2 = at follow-up.

Tables

Table 1. Characteristics of Post-SARS-CoV-2 Individuals

Demographics	
Age in years, mean ± SD	55.79 ± 7.25
Female sex at birth, %	44.2
Education in years, mean ± SD	15.83 ± 2.52
Current smokers, %	5.4
Allergic rhinitis, %	33.3
Diabetes, %	4.4
COVID-19	
Days between first positive SARS-CoV-2 PCR test and baseline (T1), mean ± SD	253.15 ± 84.46
Days between first positive SARS-CoV-2 PCR test and follow-up (T2), mean ± SD	663.51 ± 109.74
Hospitalization, %	8.4
Olfaction and olfactory bulb volume	
Subjective olfactory dysfunction at acute infection, %	67.1
Olfactory dysfunction severity (VAS), acute infection, mean ± SD	7.62 ± 2.76
Subjective olfactory dysfunction, T1, %	21.0
Olfactory dysfunction severity (VAS), T1, mean ± SD	3.79 ± 1.78
Subjective olfactory impairment, T2, %	17.5
Olfactory dysfunction severity (VAS), T2, mean ± SD	2.96 ± 2.10
Olfactometry score, T2, mean ± SD	10.18 ± 1.78
Olfactory bulb volume in mm^3, T1, mean ± SD	45.53 ± 12.85
Neuropsychological scores	
Trail Making Test B, T1, mean ± SD	69.96 ± 24.84

Word List Recall Test, T1, mean ± SD	8.51 ± 1.67
Animal Naming Test, T1, mean ± SD	28.25 ± 6.05
Mini Mental State Exam, T1, mean ± SD	28.42 ± 1.24
Patient Health Questionnaire 9, T1, mean ± SD	3.54 ± 3.69
EQ5D, T1, mean ± SD	80.74 ± 14.42

Abbreviations: PCR = polymerase chain reaction, post-SARS-CoV-2 = individuals who have recovered from a severe acute respiratory coronavirus type 2 infection, SD = standard deviation, T1 = at baseline, T2 = at follow-up.


a)
b)
c)


a)
% subjects with olfactory impairment
Avg. severity of impairment (VAS)
Acute infection
T1
T2
b)
eta_p^2 : 0.01
p : 0.211
Olfactometry score, T2
Normal
Impaired
Olfactory function at acute infection
eta_p^2 : 0.19
p : <0.005
Olfactory function, T1
eta_p^2 : 0.22
p : <0.005
Olfactory function, T2
c)
eta_p^2 : 0.00
p : 0.837
Olfactory bulb volume (mm³), T1
Olfactory function at acute infection
eta_p^2 : 0.03
p : 0.046
Olfactory function, T1
eta_p^2 : 0.03
p : 0.036
Olfactory function, T2
d)
r_{sp} = 0.161
p = 0.016
Days from positive PCR to Examination; Acute infection → T1
e)
r_{sp} = 0.154
p = 0.025
Olfactory bulb volume (mm³), T1
f)
eta_p^2 : 0.06
p : 0.018
Still impaired
Convalescent
Olfactory function, T2